- Home
- Weight Management & Metabolism
- CagriSema
Weight Management
CagriSema
Cagrilintide + semaglutide · Investigational combination
An investigational once-weekly combination of cagrilintide and semaglutide.
- Partner pharmacy
- Personal assistance
- Discreet delivery
Shipping & Delivery
- Normally dispatched within 24 hours of payment confirmation.
- UPS Express · A$25 · Approx. 7–9 business days
- Registered Mail · A$15 · Approx. 14–20 business days
For research use only.
Not intended for human or animal consumption, nor for medical, personal or diagnostic use. By purchasing this product, you confirm that you are qualified to handle research materials.
What is known so far
CagriSema combines cagrilintide, a long-acting amylin analogue, with the GLP‑1 receptor agonist semaglutide in a once-weekly injection. It is being studied in clinical trials and has no marketing authorisation.
It has no marketing authorisation as a medicine in this market. This page summarises the state of research and does not describe proven clinical benefits.
Product information
Patient information leafletNot available: not an authorised medicine
Summary of Product CharacteristicsNot available: not an authorised medicine
Related
Weight Management 
